This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months.
Methods: We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake value ratio. We assessed the predictive accuracy of the high and low NAB groupings based on progression to mild cognitive impairment or AD according to clinical reclassification at 54-month follow-up.
Results: Twelve percent of HCs with estimated high NAB progressed in comparison to 5% of HCs with estimated low NAB (odds ratio = 2.4). Forty percent of the participants with MCI who had estimated high NAB progressed in comparison to 5% of the participants with MCI who had estimated low NAB (odds ratio = 12.3). These ratios are in line with those reported for Pittsburgh compound B–PET results. Individuals with estimated high NAB had faster rates of memory decline than those with estimated low NAB.
Conclusion: These findings suggest that a simple blood-based signature not only provides estimates of NAB but also predicts cognitive decline and disease progression, identifying individuals at risk of progressing toward AD at the prodromal and preclinical stages.
GLOSSARY
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- AIBL=
- Australian Imaging, Biomarker and Lifestyle;
- ANOVA=
- analysis of variance;
- AUC=
- area under the curve;
- BBE=
- blood-based estimate;
- BeCKeT=
- Before the Centiloid Kernel Transformation;
- CDR=
- Clinical Dementia Rating;
- CI=
- confidence interval;
- CoxPH=
- Cox proportional hazards;
- CXCL-13=
- chemokine ligand 13;
- FBP=
- 18F-florbetapir;
- FLUTE=
- 18F-flutemetamol;
- HC=
- healthy control;
- IgM-1=
- immunoglobulin M-1;
- IL-17=
- interleukin 17;
- MCI=
- mild cognitive impairment;
- NAB=
- neocortical β-amyloid burden;
- OR=
- odds ratio;
- PiB=
- Pittsburgh compound B;
- PPY=
- pancreatic polypeptide;
- ROC=
- receiver operating characteristic;
- SUV=
- standardized uptake value;
- SUVR=
- standardized uptake value ratio;
- VCAM-1=
- vascular cell adhesion molecule 1
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received January 17, 2016.
- Accepted in final form June 1, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Topics Discussed
Alert Me
Recommended articles
Apolipoprotein E genotype and in vivo amyloid burden in middle-aged Hispanics
Plasma apolipoprotein E and Alzheimer disease risk
Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults
β-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia